亚日韩在线中文字幕亚洲,国产在线播放鲁啊鲁视频,张柏芝手扒性器全部图片,亚洲成无码电影在线观看

NK-92 拉丁名

(ATCC? CRL-2407?) 統(tǒng)一編號 

Organism Homo sapiens, human

Tissue peripheral blood

Cell Type natural killer cell; NK cell

Product Format 提供形式 frozen

Morphology lymphoblast Culture Properties suspension, multicell aggregates

Biosafety Level 生物安全等級 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease malignant non-Hodgkin's lymphoma Age 50 years Gender male Ethnicity Caucasian

Applications 用途 This cell line is a suitable transfection host.

The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays.

NK-92 cells (after irradiation to prevent proliferation) can be used effectively for immunological ex vivo purging of leukemia from blood without compromising hematopoietic cell function.

Storage Conditions 保藏條件 liquid nitrogen vapor phase

 Derivation NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma.

Clinical Data 50 years Caucasian, White male

Antigen Expression CD2 +, CD7 +, CD11a +, CD28 + , CD45 +, CD54 +, CD56 +, CD1 -, CD3 -, CD4 -, CD5 -, CD8 -, CD10 -, CD14 -, CD16 -, CD19 -, CD20 -, CD23 -, CD34 -, HLA-DR -

Comments 注釋 The cell line is dependent on the presence of recombinant Il-2 and a dose as low as 10 U/mL is sufficient to maintain proliferation; cells will die within 72 hours in the absence of IL-2.

NK-92 cells have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR.

ATCC confirmed this cell line is positive for the presence of Epstein-Barr viral DNA sequences via PCR.

Complete Growth Medium The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate .

To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; 100-200 U/ml recombinant IL-2; adjust to a final concentration of 12.5% horse serum and 12.5% fetal bovine serum.

Subculturing Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 2 to 3 X 105 viable cells/mL.

These cells tend to grow in aggregates that may lose viability when they are dispersed. Accurate counts and viabilities may not be possible. Corning? T-75 flasks (catalog #431464) are recommended for subculturing this product.

NK-92 cells are extremely sensitive to overgrowth and media exhaustion.

Medium Renewal:

Replace with fresh medium every 2 to 3 days (depending on cell density) Cryopreservation Freeze medium: 50% FBS; 40% complete growth medium ; 10% DMSO.

Storage temperature 保藏溫度 : liquid nitrogen vapor phase

Culture Conditions 培養(yǎng)條件 

Atmosphere 需氧情況 : air, 95%; carbon dioxide (CO2), 5%

Temperature 培養(yǎng)溫度 : 37℃

Growth Conditions 生長條件 : Successful growth of this cell line is very dependent upon the quality of IL-2 used in the growth medium.ATCC recommends using the highest quality IL-2 available.

STR Profile Amelogenin: X,Y

CSF1PO: 11,12

D13S317: 9,12

D16S539: 11,12

D5S818: 12,13

D7S820: 10,11

THO1: 6,9.3

TPOX: 8 vWA: 18

Name of Depositor 寄存人 Conkwest Inc.

References  參考文獻 Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260

Klingemann HG, et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301

Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666

Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869

Komatsu F, Kajiwara M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151

Yan Y, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753

Maki G, et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501

Nagashima S, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023

Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052

Restrictions The NK-92 cell line was deposited at the ATCC by NantKwest Inc. and is available with the following restrictions:

Not-for-profit academic institutions may use this cell line for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes, including but not limited to the testing or validation of any commercial product or instrument.

Nor can the cells be distributed to third parties for any reason, including purposes of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community.

They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied.

For-profit commercial organizations must obtain a research use and/or a commercial license directly from NantKwest Inc. For instructions on how to proceed, please contact NantKwest’s licensing department via email at contact@nantkwest.com.

References  參考文獻 Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260

Klingemann HG, et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301

Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666

Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869

Komatsu F, Kajiwara M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151

Yan Y, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753

Maki G, et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501

Nagashima S, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023

Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052